Elanco動物保健公司預計2025年第一季度收入在11.55億美元至11.8億美元之間，相比市場共識預期的12.11億美元有所下降，調整後每股收益預計在0.29美元至0.34美元之間，高於市場共識的0.30美元。公司預計第一季度收入將受到約4000萬美元的外匯不利影響，剔除外匯不利影響和水產剝離，預計收入將增長2%至4%。此外，公司預計運營費用同比將上升6%至8%，主要由於全球創新產品組合的戰略投資。第一季度調整後的息稅折舊攤銷前利潤（EBITDA）預計將受到約1500萬美元的外匯影響。公司預計第一季度調整後的有效稅率將在中個位數範圍，全年預期稅率爲21%至22%。

以上內容來自Benzinga Earnings專欄，原文如下：

In the first quarter, the company expects a headwind to revenue of approximately $40 million from the unfavorable impact of foreign exchange rates compared to prior year. Excluding the unfavorable impact of foreign exchange rates and the aqua divestiture, the company expects 2% to 4% revenue growth.

The company expects operating expenses up 6% to 8% year over year in constant currency with strategic investment in the global launches of the innovation portfolio. First quarter adjusted EBITDA includes an expected foreign exchange rate impact of approximately $15 million compared to prior year.

The company expects first quarter adjusted effective tax rate to be in the mid-single digit range as a result of a discrete tax item that will also benefit the full-year expected tax rate of 21% to 22%.